Xeris Biopharma Holdings, Inc. (XERS): Total Assets
$383.53M
As of 2025-12-31
$411.90M
As of 2026-06-30
+3.6%
3-year compound annual growth
+19.2%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $383.53M | +18.7% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $323.06M | +0.1% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $322.60M | -6.4% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $344.52M | +13.2% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $304.36M | +91.2% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $159.15M | n/a | 2022-03-11, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $383.53M | +18.7% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $396.90M | +13.1% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $225.87M | -2.9% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $826.14M | +595.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $399.48M | +2.7% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $817.15M | +193.0% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.56B | +65.7% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $717.90M | -34.2% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $726.16M | -11.8% |
Compare XERS, IRWD, EOLS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗